INTRODUCTION
The conventional treatment of malignant tumors include local ways such as surgery, radiotherapy with the combination of chemotherapy, hormone therapy and biological treatment. 1 For oncological patients with metastasis is the most used chemotherapeutic doxorubicin (DOX). 2 Treatment response is in the range of 25% and 33%, with a median progression of 3.6 months and a median survival of 8.9 months. Despite DOX therapeutic efficacy it exhibits high cardiotoxicity. 3 This side effect limits the cumulative applied dose. Heart muscle damage is reported in 3% of patients at 400 mg/m 2 , 7% at 500 mg/m 2 , and in more than 15% of patients heart damage at 700 mg/m. 4 The development of new type of nanotransporter is focused on the decrease of DOX induced cardiotoxicity. Several nanotechnological approaches have been successfully used for the decrease of side effects induced * Author to whom correspondence should be addressed.
by various anthracycline antibiotics utilized for hematological malignancies and solid tumors therapy. 5 6 The nanotransporter modification of therapeutics allows its targeting preferentially to cancer cell and moreover could increase level of anticancer drug in the final destination without increasing the side effects. Additionally, drugs closed in a nano-cage are protected from intracellular enzymatic degradation or endosomal translocation. Recently, chitosan nanoparticles have gained more attention due to their stability, low toxicity and simple preparation in the field of targeted drug transport. 7 Deacetylated chitosan backbone of glucosamine clusters shows high electrostatic interactions with biomolecules, metals (Zn, Se) and/or peptides. 8 9 It is generally known that metallothione in (MT) is a metal-binding protein responsible for zinc homeostasis and heavy metal detoxification in the organism. In our previous published work, we showed the significant increase of MT in malignant tumors. [10] [11] [12] Furthermore, it has been estimated that the MT level in breast cancer significantly increase due to higher metabolic activity of the tumor tissue and defense system against oxidative stress induced by chemotherapeutics. [13] [14] [15] The aim of our study was to design a chitosan based nanotransporter for DOX which was modified by zinc ions (Zn-ChNPs-DOX). Zinc ions were involved for higher uptake from the bloodstream via interaction with MT. We suppose the free -SH groups of MT bind preferentially to the structure of Zn-ChNPs-DOX. In the experiment, chitosan nanotransporter was designed and subsequently studied by biophysical methods.
EXPERIMENTAL DETAILS
2.1. Chemicals Doxorubicin, chitosan, zinc chloride, metallothione in II from rabbit liver, ssDNA (AGGATCTGATCC) ACS water and other chemicals were purchased from Sigma-Aldrich (St. Louis, USA) in ACS purity unless noted otherwise.
Chitosan Nanoparticles Preparation
12.5 mg of low MW chitosan was dissolved in 5 mL of 3% acetic acid. DOX (30 M) was added to the chitosan solution under stirring (3 hours, 24 C). After DOX dissolution, the sodium tripolyphosphate (0.25% w/v) was added dropwise. The unbounded DOX was removed using centrifugation procedure. The solution was transferred in to the tubes and centrifugated 10 min, 14000 rpm (Eppendorf centrifuge, Hamburg, Germany). The pellet was dissolved in 5 mL of 3% acetic acid.
Preparation of Chitosan Nanoparticles with
Encapsulated DOX Modified by Zinc ZnCl 2 was added to chitosan nanoparticles (ChNPs) with encapsulated DOX at a final ZnCl 2 concentration of 1.0 mM. The solution was stirred for 30 min before use.
Electrochemical Determination of Zinc Ions
Determination of Zn 2+ by difference pulse voltammetry (DPV) was performed at 663 VA Stand (Metrohm, Switzerland) connected with AUTOLAB Analyzer (Metrohm-Autolab B.V., Utrecht, The Netherlands). Adsorptive transfer technique and a standard cell with three electrodes was used for measurement. A hanging mercury drop electrode (HMDE) with a drop area of 0.4 mm 2 was employed as the working electrode. An Ag/AgCl/3 M KCl electrode acted as the reference and platinum electrode was auxiliary. For data processing NOVA software (Metrohm, Utrecht, The Netherlands) was employed. The analyzed samples were deoxygenated prior to measurements by purging with argon (99.999%). Acetate buffer (0.2 M sodium acetate and 0.2 M acetic acid, pH = 5) was used as a supporting electrolyte. The parameters of the measurement were as follows: initial potential 0 V, end potential −1 7 V, deoxygenating with argon 30 s, accumulation time 120 s, step potential 5 mV, modulation amplitude 25 mV, volume of injected sample 5 L, volume of measurement cell 2 mL (5 L of sample and 1995 L supporting buffer).
Fluorometric and Spectroscopic
Measurements of Doxorubicin Fluorescence spectra were acquired by a multifunctional microplate reader Tecan Infinite 200 PRO (TECAN, Switzerland). Excitation wavelength for DOX was 480 nm. The fluorescence scan of DOX was measured within the range from 510-850 nm per 2-nm steps. The detector gain was set to 100. Absorbance of ssDNA was measured at = 260 nm. Each absorbance value is an average of three measurements. The samples for measurements (2 L) were placed in 96 well plate by Tecan (TECAN, Switzerland). All measurements were performed at 25 C controlled by the Tecan Infinite 200 PRO (TECAN, Switzerland).
Metallothionein Scavenging of the Free Radicals
Spectrophotometric measurements of 2,2-diphenyl-1-picrylhydrazyl (DPPH) were carried out using an automated chemical analyser BS-200 (Mindray, Shenzhen, China). Reagents and samples were placed on cooled sample holder (4 ± 1 C) and automatically pipetted directly into plastic cuvettes. Incubation proceeded at 37 0 ± 0 1 C. Mixture was consequently stirred. The washing steps of pipetting needle with distilled water (18 m ) were done during the pipetting. For detection itself, the following range of wavelengths were used-340, 380, 412, 450, 505, 546, 570, 605, 660, 700, 740 and 800 nm. The instrument was operated using the BS-200 software (Mindray, Shenzhen, China).
The DPPH test is based on the ability of the stable DPPH free radical to react with hydrogen donors. The DPPH
• radical displays an intense UV-VIS absorption spectrum. In this test, a solution of radical is decolorized after reduction with antioxidant (AH) or a radical (R • ) in accordance with the following scheme:
150 L of DPPH reagent was pipetted into a plastic cuvette. Subsequently, 15 L of sample was added to the solution. DPPH conducts a strong absorption in the UV-VIS spectrum, absorbance was measured for 12 min at = 505 nm. To assess the production of free radicals, the absorbance difference of the reagent without sample and reagent with sample after ten-minute incubation was taken. After subtraction of the blank value the biggest absorbance difference was taken as 100% of the amount of free radicals. The higher the amount of free radicals was, the higher was the oxidative stress.
Ellman Assay
For analysis of thiol groups was used an Ellman spectrophotometric assay. 277 L of Ellman reagent (R1)
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Zinc-Modified Nanotransporter of Anticancer Drugs for Targeted Therapy: Biophysical Analysis (2 mM 5,5 -dithiobis(2-nitrobenzoic acid) in 2 mM Na 2 (CH 3 COO 2 )) was pipetted in the cuvette, subsequently the 45 L of sample and 33 L of reagent (R2) (1 M CH 3 COOH) were added to the mixture. The mixture was incubated for 10 min at 37 C. The absorbance was recorded at 405 nm. The Ellman assay was carried out using an automated chemical analyser BS-200 (Mindray, Shenzhen, China). Reagents and samples were placed on a cooled sample holder (4 ± 1 C) and automatically pipetted directly into the plastic cuvettes. Incubation proceeded at 37 0 ± 0 1 C. Mixture was consequently stirred. The washing steps of pipetting needle with distilled water (18 m ) were done during the pipetting. The instrument was operated using the BS-200 software (Mindray, Shenzhen, China).
Descriptive Statistics
Data were processed using MICROSOFT EXCEL ® (USA). Results are expressed as mean ±standard deviation (S.D.) unless noted otherwise.
RESULTS AND DISCUSSION
The unique properties of chitosan were employed for DOX delivery to the target tissue with the utilization of zinc ions. The DOX encapsulation by chitosan polymeric cage decorated by Zn 2+ via electrostatic interaction is shown in Figure 1 . The formation of the chitosan nanoparticles and its interaction with metallothione in is further biophysically examinated.
Chitosan Nanoparticles Characterization
We used size measurement and Z-potential characterization of colloidal state of the nanoparticle system in our experiment. Figure 2 (A) demonstrated that size of the nanoparticles was found to be 40 ± 3 nm. Measurement Figure 1 . Simplified scheme of chitosan nanotransporter focused on tumor tissue. Cancer cells highly exprime molecules of metallothionein in the comparison with a healthy tissue. 21 Designed nanotransporter Zn-ChNPs-DOX preferentially binds into the active metallothionein clusters.
of the Z-potential (or charge density) provides important information about predicting their binding capacity. We confirmed that chitosan nanoparticles carry positive charge approximately of 50 mV. We tested the dependence of tripolyphosphine (TPP) addition on Z-potential of the formed nanoparticles. Figure 2(B) shows that the highest Z-potential is caused by 0.0025 M addition of TPP. The higher TPP addition causes a decrease of the Z-potential. This effect could be explained due to the accumulation of counterions near the surface causing charges and subsequently reducing the Z-potential.
Zinc Binding to the Structure of ChNPs
Electrochemical measurement was used due to its sensitivity and ability to monitor the course of interactions. Figure 2 (C) shows a characteristic peak of Zn 2+ with the potential about −1.0 V. Although, chitosan alone does not exhibit electrochemical activity and after interaction with zinc ions the electrochemical signal shifts to more positive potential. Simultaneously, the additional electrochemical signal occurs at the potential about −0.2 V depending on the zinc concentration. This result could be explained by the formation of a zinc-chitosan complex. The dependence of potential and electrochemical signal on zinc concentration is summarized in the graph Figure 2(D) . From the obtained data we could conclude that the higher concentration of chitosan caused a decrease in the electrochemical signal of zinc up to a concentration of 300 g/mL. Therefore, higher concentrations of chitosan do not have an effect on the zinc electrochemical signal. Simultaneously, we observed that the higher concentration of chitosan shifts zinc electrochemical potential from −0.99 to −0.93 V. In summary, our results confirmed the formation of a chitosan-zinc complex. Considering the fact, that chitosan is used for electrode coating, especially in biosensors, the observed interaction course is consistent with other published work. 
Doxorubicin Encapsulation
We involved a fluorescence as a suitable analytical tool for characterization and determination the encapsulation efficiency of chitosan nanoparticles. 3 M DOX shows 9% quantum yield which enables the sensitive detection. 17 Firstly, the dependence of fluorescence signal on DOX concentration was evaluated. The obtained calibration curve shows a linear trend in the concentration range from 0 to 30 M with the following linear equation: y = 1601 2x + 2012 3 and R 2 = 0 9944 ( Fig. 3(A) ). The limit of DOX fluorometric detection was found to be 0.09 M (3 S/N). For the determination of the encapsulation efficiency, the doxorubicin itself (30 M) and encapsulated DOX (DOX-ChNPs) fluorescence intensity was compared. The decrease of the fluorescence intensity for DOX-ChNPs could be observed from the emission spectra (Fig. 3(B) ). The concentration of an encapsulated DOX was calculated to be 6 M which corresponds to 20% encapsulation effectivity.
The goal of our study was to encapsulate DOX into chitosan nanoparticles and to minimize the number of molecules on the nanoparticles surface. We took the advantage of DOX intercalation ability into the structure of DNA to determine the presence of DOX (30 M) on ChNPs surface. The intercalated DOX into the (1 mM) DNA showed a significant decrease of the fluorescence signal (Fig. 3(C), on top) . Consequently, the DOX-ChNPs was analyzed before and after the purification step which removes unbounded DOX. The obtained results demonstrated a higher fluorescence signal for the unpurified DOX-ChNPs which could be explained due to the removal of unbound DOX. In the presence of DNA, the fluorescence signal decrease occurs in both cases. To evaluate the changes of fluorescence signals the size of the difference was calculated before and after purification of ChNP-DOX. The higher decrease oft he fluorescence signal was estimated in the case of unpurified DOX-ChNPs which means that DOX appears on the surface of the nanoparticles at low concentration. Obtained results are in good agreement with other studies based on the doxorubicinchitosan nanoparticle formation. [18] [19] [20] Our approach excels in the simplicity and availability of the experimental design.
ChNPs-DOX Interaction with MT
One proposed mechanism of action of DOX after its metabolization is the formation of a number of radicals, which lead to a cell damage and later to apoptosis. In several malignant tumors there is a significant increase of thiol levels (explained by the increase of MT synthesis), that presumably scavenge molecules used for damaging the tumor cells. Due to this effect, the tumor cell resistance for the used cytostatic increases. In our study, we aimed to assess the effect of thiols capable of capturing the radicals, especially MT. To date, very little attention has been paid to this issue and mechanisms of these interactions have not been described yet. In this experiment, DPPH radical was used.
Figure 4(A) shows the effect of DOX added to the DPPH reaction mixture at different concentrations. The observed signals are within a 10% deviation due to a laboratory error, and the resultant DPPH signal does not change at any of the tested doxorubicin concentrations. MT (1000 g/mL) scavenged the DPPH radical very intensively (signal change by more than 200%), see Figure 4 (B). In case that DOX was added to the MT, the progressive blocking of the -SH groups for Ellman's reagent (Fig. 4(B) , grey bars) was observed with the increase of the DOX concentration, and after 100 M addition of DOX the resulting MT signal change was more than 100%.
The results indicate the considerable ability of MT to quench the DPPH radical in the presence of 50 M DOX, the signal change was found to be between 50-60%. Figure 4 (C) shows the effect of different amounts of MT and its ability to quench the DPPH radical. The result clearly demonstrated the notable ability of thiol compounds to react with radical molecules and thus reduce the effectiveness of antitumor treatment (1 g of MT reacts with DPPH by changing the signal by 0.2145). For these reasons, it is necessary to look for suitable tools to overcome this natural biological base of resistance.
CONCLUSION
To the conclusion, new nanotransporter is characterized by its bioavailability, increased uptake of drug from the blood stream at the site of tumor tissue, and low toxicity to non-targeted tissues. The results showed that the chitosan nanoparticle closes DOX in its structure and Zn 2+ ions are bound to its surface. DOX-ChNPs of size 40 nm were successfully designed. The fluorescence quenching effect of doxorubicin was used for the evaluation of nonencapsualted DOX molecules on the nanoparticle surface. The results demonstrated the formation of chitosan nanoparticles and their ability to bind on the MT protein, which plays an important role in the breast cancer.
